Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy: evidence-based treatment and monitoring recommendations.

IF 3.3 2区 医学 Q1 PERIPHERAL VASCULAR DISEASE
Ariel Wang, Constantinos Koshiaris, Lucinda Archer, Richard D Riley, Kym I E Snell, Richard Stevens, Amitava Banerjee, Juliet A Usher-Smith, Subhashisa Swain, Andrew Clegg, Christopher E Clark, Rupert A Payne, F D Richard Hobbs, Richard J McManus, James P Sheppard
{"title":"Developing prediction models for electrolyte abnormalities in patients indicated for antihypertensive therapy: evidence-based treatment and monitoring recommendations.","authors":"Ariel Wang, Constantinos Koshiaris, Lucinda Archer, Richard D Riley, Kym I E Snell, Richard Stevens, Amitava Banerjee, Juliet A Usher-Smith, Subhashisa Swain, Andrew Clegg, Christopher E Clark, Rupert A Payne, F D Richard Hobbs, Richard J McManus, James P Sheppard","doi":"10.1097/HJH.0000000000004032","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Evidence from clinical trials suggests that antihypertensive treatment is associated with an increased risk of common electrolyte abnormalities. We aimed to develop and validate two clinical prediction models to estimate the risk of hyperkalaemia and hyponatraemia, respectively, to facilitate targeted treatment and monitoring strategies for individuals indicated for antihypertensive therapy.</p><p><strong>Design and methods: </strong>Participants aged at least 40 years, registered to an English primary care practice within the Clinical Practice Research Datalink (CPRD), with a systolic blood pressure reading between 130 and 179 mmHg were included the study. The primary outcomes were first hyperkalaemia or hyponatraemia event recorded in primary or secondary care. Model development used a Fine-Gray approach with death from other causes as competing event. Model performance was assessed using C-statistic, D-statistic, and Observed/Expected (O/E) ratio upon external validation.</p><p><strong>Results: </strong>The development cohort included 1 773 224 patients (mean age 59 years, median follow-up 6 years). The hyperkalaemia model contained 23 predictors and the hyponatraemia model contained 29 predictors, with all antihypertensive medications associated with the outcomes. Upon external validation in a cohort of 3 805 366 patients, both models calibrated well (O/E ratio: hyperkalaemia 1.16, 95% CI 1.13-1.19; hyponatraemia 1.00, 95% CI 0.98-1.02) and showed good discrimination at 10 years (C-statistic: 0.69, 95% CI 0.69-0.69; 0.80, 95% CI 0.80-0.80, respectively).</p><p><strong>Conclusion: </strong>Current clinical guidelines recommend monitoring serum electrolytes after initiating antihypertensive treatment. These clinical prediction models predicted individuals' risk of electrolyte abnormalities associated with antihypertensive treatment and could be used to target closer monitoring for individuals at a higher risk, where resources are limited.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HJH.0000000000004032","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Evidence from clinical trials suggests that antihypertensive treatment is associated with an increased risk of common electrolyte abnormalities. We aimed to develop and validate two clinical prediction models to estimate the risk of hyperkalaemia and hyponatraemia, respectively, to facilitate targeted treatment and monitoring strategies for individuals indicated for antihypertensive therapy.

Design and methods: Participants aged at least 40 years, registered to an English primary care practice within the Clinical Practice Research Datalink (CPRD), with a systolic blood pressure reading between 130 and 179 mmHg were included the study. The primary outcomes were first hyperkalaemia or hyponatraemia event recorded in primary or secondary care. Model development used a Fine-Gray approach with death from other causes as competing event. Model performance was assessed using C-statistic, D-statistic, and Observed/Expected (O/E) ratio upon external validation.

Results: The development cohort included 1 773 224 patients (mean age 59 years, median follow-up 6 years). The hyperkalaemia model contained 23 predictors and the hyponatraemia model contained 29 predictors, with all antihypertensive medications associated with the outcomes. Upon external validation in a cohort of 3 805 366 patients, both models calibrated well (O/E ratio: hyperkalaemia 1.16, 95% CI 1.13-1.19; hyponatraemia 1.00, 95% CI 0.98-1.02) and showed good discrimination at 10 years (C-statistic: 0.69, 95% CI 0.69-0.69; 0.80, 95% CI 0.80-0.80, respectively).

Conclusion: Current clinical guidelines recommend monitoring serum electrolytes after initiating antihypertensive treatment. These clinical prediction models predicted individuals' risk of electrolyte abnormalities associated with antihypertensive treatment and could be used to target closer monitoring for individuals at a higher risk, where resources are limited.

发展抗高血压患者电解质异常的预测模型:循证治疗和监测建议。
目的:来自临床试验的证据表明,抗高血压治疗与常见电解质异常的风险增加有关。我们的目的是建立和验证两种临床预测模型来分别估计高钾血症和低钠血症的风险,以促进针对个体的抗高血压治疗和监测策略。设计和方法:参与者年龄在40岁以上,在临床实践研究数据链(CPRD)的英国初级保健实践中注册,收缩压读数在130至179 mmHg之间。主要结局是在初级或二级护理中记录的首次高钾血症或低钠血症事件。模型开发使用了Fine-Gray方法,将其他原因导致的死亡作为竞争事件。采用c统计量、d统计量和外部验证的观察/预期(O/E)比评估模型性能。结果:发展队列包括1 773 224例患者(平均年龄59岁,中位随访6年)。高钾血症模型包含23个预测因子,低钠血症模型包含29个预测因子,所有抗高血压药物均与结果相关。在3 805 366例患者队列的外部验证中,两个模型都校准良好(O/E比:高钾血症1.16,95% CI 1.13-1.19;低钠血症1.00,95% CI 0.98-1.02),并在10年时表现出良好的鉴别(C-statistic: 0.69, 95% CI 0.69-0.69;0.80, 95% CI分别为0.80-0.80)。结论:目前的临床指南建议在开始抗高血压治疗后监测血清电解质。这些临床预测模型预测了个体与抗高血压治疗相关的电解质异常风险,并可用于对资源有限的高风险个体进行更密切的监测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Hypertension
Journal of Hypertension 医学-外周血管病
CiteScore
7.90
自引率
6.10%
发文量
1389
审稿时长
3 months
期刊介绍: The Journal of Hypertension publishes papers reporting original clinical and experimental research which are of a high standard and which contribute to the advancement of knowledge in the field of hypertension. The Journal publishes full papers, reviews or editorials (normally by invitation), and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信